# Takashi Kohno

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/takashi-kohno/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,168 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 84 |
| i10-index | 307 |
| Last Known Institution | National Cancer Centre Japan |
| OpenAlex ID | https://openalex.org/A5025520229 |
| ORCID iD | https://orcid.org/0000-0002-5371-706X |
| Works | 836 |

## Researcher papers

- [Comprehensive genomic profiles of small cell lung cancer](https://scholariq.org/papers/comprehensive-genomic-profiles-of-small-cell-lung-cancer/)
- [Identification of Genes Upregulated in <i>ALK</i> -Positive and <i>EGFR/KRAS/ALK</i> -Negative Lung Adenocarcinomas](https://scholariq.org/papers/identification-of-genes-upregulated-in-i-alk-i-positive-and-i-egfr-kras-alk-i/)
- [Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases](https://scholariq.org/papers/large-scale-genome-wide-association-study-in-a-japanese-population-identifies/)
- [Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia](https://scholariq.org/papers/genome-wide-association-analysis-identifies-new-lung-cancer-susceptibility-loci/)
- [Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial](https://scholariq.org/papers/vandetanib-in-patients-with-previously-treated-ret-rearranged-advanced-non-small/)
- [Prevalence and specificity of LKB1 genetic alterations in lung cancers](https://scholariq.org/papers/prevalence-and-specificity-of-lkb1-genetic-alterations-in-lung-cancers/)
- [Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines](https://scholariq.org/papers/frequent-brg1-smarca4-inactivating-mutations-in-human-lung-cancer-cell-lines/)
- [Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.](https://scholariq.org/papers/beyond-alk-ret-ros1-and-other-oncogene-fusions-in-lung-cancer/)
- [Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma](https://scholariq.org/papers/epidermal-growth-factor-receptor-tyrosine-kinase-defines-critical-prognostic/)
- [Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis](https://scholariq.org/papers/therapeutic-priority-of-the-pi3k-akt-mtor-pathway-in-small-cell-lung-cancers-as/)
- [C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan](https://scholariq.org/papers/c-cat-the-national-datacenter-for-cancer-genomic-medicine-in-japan/)
- [Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors](https://scholariq.org/papers/significance-of-molecular-classification-of-ependymomas-c11orf95-rela-fusion/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [National Cancer Centre Japan](https://scholariq.org/institutions/national-cancer-centre-japan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.